SI1397364T1 - Novi pirolni derivati kot farmacevtske uäśinkovine - Google Patents

Novi pirolni derivati kot farmacevtske uäśinkovine

Info

Publication number
SI1397364T1
SI1397364T1 SI200230626T SI200230626T SI1397364T1 SI 1397364 T1 SI1397364 T1 SI 1397364T1 SI 200230626 T SI200230626 T SI 200230626T SI 200230626 T SI200230626 T SI 200230626T SI 1397364 T1 SI1397364 T1 SI 1397364T1
Authority
SI
Slovenia
Prior art keywords
pharmaceutical agents
pyrrole derivatives
novel pyrrole
novel
derivatives
Prior art date
Application number
SI200230626T
Other languages
English (en)
Slovenian (sl)
Inventor
Jason Scott Sawyer
Douglas Wade Beight
Paola Ciapetti
Todd Vincent Decollo
Alexander Glenn Godfrey
Theodore Goodson Jr
David Kent Herron
Hong-Yu Li
Junkai Liao
William Thomas Mcmillen
Shawn Christopher Miller
Nicolas Anthony Mort
Jonathan Michael Yingling
Edward C R Smith
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SI1397364T1 publication Critical patent/SI1397364T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
SI200230626T 2001-05-24 2002-05-13 Novi pirolni derivati kot farmacevtske uäśinkovine SI1397364T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29346401P 2001-05-24 2001-05-24
EP02744115A EP1397364B1 (en) 2001-05-24 2002-05-13 Novel pyrrole derivatives as pharmaceutical agents
PCT/US2002/011884 WO2002094833A1 (en) 2001-05-24 2002-05-13 Novel pyrrole derivatives as pharmaceutical agents

Publications (1)

Publication Number Publication Date
SI1397364T1 true SI1397364T1 (sl) 2007-12-31

Family

ID=23129192

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200230626T SI1397364T1 (sl) 2001-05-24 2002-05-13 Novi pirolni derivati kot farmacevtske uäśinkovine

Country Status (37)

Country Link
US (1) US7087626B2 (cs)
EP (1) EP1397364B1 (cs)
JP (2) JP4519407B2 (cs)
KR (1) KR100861630B1 (cs)
CN (2) CN1269820C (cs)
AR (1) AR036034A1 (cs)
AT (1) ATE368041T1 (cs)
AU (1) AU2002339268B2 (cs)
BR (1) BR0209939A (cs)
CA (1) CA2446820C (cs)
CO (1) CO5540282A2 (cs)
CY (1) CY1106871T1 (cs)
CZ (1) CZ303808B6 (cs)
DE (1) DE60221392T2 (cs)
DK (1) DK1397364T3 (cs)
DZ (1) DZ3506A1 (cs)
EA (1) EA007782B1 (cs)
EC (1) ECSP034859A (cs)
EG (1) EG25614A (cs)
ES (1) ES2289116T3 (cs)
HR (1) HRP20030961B1 (cs)
HU (1) HU228844B1 (cs)
IL (2) IL158512A0 (cs)
MX (1) MXPA03010630A (cs)
MY (1) MY134586A (cs)
NO (1) NO326701B1 (cs)
NZ (1) NZ528525A (cs)
PE (1) PE20030117A1 (cs)
PL (1) PL221339B1 (cs)
PT (1) PT1397364E (cs)
SI (1) SI1397364T1 (cs)
SK (1) SK287857B6 (cs)
SV (1) SV2003001054A (cs)
TW (1) TWI329644B (cs)
UA (1) UA76461C2 (cs)
WO (1) WO2002094833A1 (cs)
ZA (1) ZA200308546B (cs)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20030961B1 (en) * 2001-05-24 2012-01-31 Eli Lilly And Company Novel pyrrole derivatives as pharmaceutical agents
DE60222465T2 (de) * 2001-12-11 2008-06-05 Smithkline Beecham Corp. Pyrazolopyridin-derivate als antiherpesmittel
ES2291664T3 (es) 2002-09-17 2008-03-01 Eli Lilly And Company Derivados de pirazolopiridina como inhibidores de la transduccion de señales de tgf beta para el tratamiento del cancer.
WO2004048383A1 (en) * 2002-11-21 2004-06-10 Eli Lilly And Company Mixed lineage kinase modulators
EP1578749A2 (en) * 2002-11-22 2005-09-28 Eli Lilly And Company Pyrazoloazepine compounds as pharmaceutical agents
UA80571C2 (en) * 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
AU2003290734A1 (en) * 2002-11-27 2004-06-23 Eli Lilly And Company Novel compounds as pharmaceutical agents
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
US7511065B2 (en) * 2003-11-12 2009-03-31 Eli Lilly And Company Mixed lineage kinase modulators
EP1723146A1 (en) 2004-03-01 2006-11-22 Eli Lilly And Company Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
SG161217A1 (en) 2005-04-01 2010-05-27 Insa Rouen New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents
PT1910370E (pt) 2005-07-22 2015-06-30 Lilly Co Eli Um pirrolo[1,2-b]pirazole mono-hidratado substituído com piridina e quinolina como inibidor do tgf-beta
AU2006279794B2 (en) * 2005-08-12 2011-04-07 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate HSP90 activity
EP1973909A2 (en) * 2005-12-22 2008-10-01 Biogen Idec MA Inc. Transforming growth factor modulators
DE102005061840A1 (de) 2005-12-23 2007-06-28 Merck Patent Gmbh Triazolderivate
CA2653217A1 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with protooncogene products
EP3254696A1 (en) 2006-10-03 2017-12-13 Genzyme Corporation Use of tgf beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
PL2217600T3 (pl) * 2007-12-12 2013-04-30 Du Pont Grzybobójcze pirazole bicykliczne
JP5490137B2 (ja) * 2008-12-19 2014-05-14 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ プロテインキナーゼ阻害薬としての二環式ピラゾール
CN102695511A (zh) * 2009-04-17 2012-09-26 舒玛健康系统有限责任公司 抑制眼部瘢痕形成的转化生长因子-β受体抑制剂的用途
AR081810A1 (es) * 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
EP2402337A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
EP2401915A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
EP2402339A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
EP2402340A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
EP2402338A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
WO2012138945A1 (en) 2011-04-08 2012-10-11 Aestus Therapeutics, Inc. Methods of treating schizophrenia with pyrazole derivative inhibitors of tgf - beta
EP2737083A1 (en) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Methods for diagnosing and treating myhre syndrome
WO2013062544A1 (en) 2011-10-26 2013-05-02 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
JP2014532712A (ja) 2011-11-02 2014-12-08 シンタ ファーマシューティカルズ コーポレーション トポイソメラーゼｉ阻害剤とｈｓｐ９０阻害剤の組合せを使用する癌療法
EP2776025A1 (en) 2011-11-02 2014-09-17 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
WO2013078286A1 (en) 2011-11-22 2013-05-30 Cornell University Methods for stimulating hematopoietic recovery by inhibiting tgf beta signaling
EA032679B1 (ru) 2012-10-05 2019-07-31 Кадмон Корпорейшн, Ллк Человеческие анти-vegfr-2/kdr-антитела
TWI443096B (zh) 2012-12-18 2014-07-01 Ind Tech Res Inst ３－（５－（４－（３－氟丙基）哌嗪－１－基）苯並咪唑－２－基）－１－氮雜薁－２－酮之單水合晶型及其製備方法與藥學組成物
AU2014214324B2 (en) * 2013-02-07 2018-07-19 Prexton Therapeutics Sa Substituted acetylene derivatives and their use as positive allosteric modulators of mGluR4
WO2014159356A1 (en) 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Compositions and methods for epithelial stem cell expansion and culture
US8975417B2 (en) * 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
ES2735099T3 (es) 2014-02-03 2019-12-16 Vitae Pharmaceuticals Llc Inhibidores de dihidropirrolopiridina de ROR-gamma
EP3189134A1 (en) 2014-09-03 2017-07-12 The Brigham and Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
JO3336B1 (ar) 2014-10-07 2019-03-13 Lilly Co Eli مركبات أمينو بيريديلوكسي بيرازول
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
EP3277673B1 (en) 2015-04-01 2022-05-04 Rigel Pharmaceuticals, Inc. Tgf-beta inhibitors
WO2016210292A1 (en) 2015-06-25 2016-12-29 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
US10301261B2 (en) 2015-08-05 2019-05-28 Vitae Pharmaceuticals, Llc Substituted indoles as modulators of ROR-gamma
CA3005658A1 (en) 2015-11-20 2017-05-26 Vitae Pharmaceuticals, Inc. Modulators of ror-gamma
CN108779437A (zh) 2016-01-08 2018-11-09 麻省理工学院 分化的肠内分泌细胞和胰岛素产生细胞的制备
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
AU2017235461B2 (en) 2016-03-15 2023-02-23 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
WO2017215506A1 (zh) * 2016-06-13 2017-12-21 南京明德新药研发股份有限公司 作为TGF-βR1抑制剂的苯并三氮唑衍生的α，β不饱和酰胺类化合物
RU2729999C1 (ru) 2016-07-29 2020-08-13 Шанхай Инли Фармасьютикал Ко., Лтд Азотсодержащее гетероциклическое ароматическое соединение, способ его получения, фармацевтическая композиция на его основе и его применение
KR20190104359A (ko) 2016-12-30 2019-09-09 프리퀀시 테라퓨틱스, 인크. 줄기/전구체 지지 세포의 자가 재생을 유도하기 위한 1h-피롤-2,5-다이온 화합물 및 이의 사용 방법
US11045472B2 (en) 2017-05-05 2021-06-29 Arcus Biosciences, Inc. Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN111225914B (zh) 2017-07-24 2022-10-11 生命医药有限责任公司 RORγ的抑制剂
RS63581B1 (sr) 2017-10-05 2022-10-31 Fulcrum Therapeutics Inc Inhibitori p38 kinaze smanjuju ekspresiju dux4 i nizvodnih gena u cilju lečenja fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
JP7362600B2 (ja) 2017-10-11 2023-10-17 エフ． ホフマン－ラ ロシュ アーゲー Ｒｉｐ１キナーゼ阻害剤として使用するための二環式化合物
JP2021035911A (ja) * 2017-11-15 2021-03-04 大日本住友製薬株式会社 縮環ピラゾール誘導体及びその医薬用途
EP3725786B1 (en) 2017-12-13 2023-08-23 GenFleet Therapeutics (Shanghai) Inc. Crystal form and salt form of tgf-bri inhibitor and preparation method therefor
CN110066276B (zh) 2018-01-24 2020-09-18 上海璎黎药业有限公司 芳香杂环化合物、其中间体、制备方法、药物组合物和应用
CN110066277B (zh) 2018-01-24 2021-07-23 上海璎黎药业有限公司 芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用
CA3093340A1 (en) 2018-03-20 2019-09-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
WO2019236766A1 (en) 2018-06-06 2019-12-12 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
WO2020019108A1 (en) 2018-07-23 2020-01-30 Guangzhou Othrotx Co., Ltd. Bisphosphonate drug conjugates
EP3837351A1 (en) 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
CN113195707A (zh) 2018-08-17 2021-07-30 频率治疗公司 用于通过上调jag-1来生成毛细胞的组合物和方法
KR102126576B1 (ko) 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
CN112839946B (zh) * 2018-10-31 2022-04-12 江苏奥赛康药业有限公司 作为TGF-βR1激酶抑制剂的双环吡唑类化合物
US20220089600A1 (en) * 2018-11-22 2022-03-24 Fundació Institut De Recerca Biomèdica (Irb Barcelona) TGFß INHIBITOR AND PRODRUGS
EA202191619A1 (ru) 2018-12-27 2021-09-28 Нексис Терапьютикс, Инк. Производные (пиридин-2-ил)амина в качестве ингибиторов tgfбета r1 (alk5) для лечения злокачественных новообразований
AU2019419414A1 (en) 2018-12-31 2023-04-06 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
KR102740196B1 (ko) 2019-01-24 2024-12-10 지앙수 아오사이캉 파마수티칼 씨오., 엘티디. TGF-β R1 키나아제 억제제로서의 5-(4-피리딜옥시)피라졸 화합물
WO2020160151A1 (en) * 2019-01-31 2020-08-06 Kyorin Pharmaceutical Co., Ltd. 15-pgdh inhibitors
JP2022527972A (ja) 2019-04-02 2022-06-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 前悪性病変を有する患者において癌を予測及び予防する方法
CN113557236B (zh) * 2019-06-10 2022-05-10 中国科学院广州生物医药与健康研究院 一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物
CN115052663A (zh) 2020-01-08 2022-09-13 辛瑟斯治疗股份有限公司 Alk5抑制剂缀合物及其用途
CN114867723B (zh) * 2020-07-23 2023-05-30 江苏奥赛康药业有限公司 作为TGF-βR1抑制剂的吡啶氧基连吡唑类化合物的盐型、晶型以及其药物组合物
WO2022063050A1 (zh) 2020-09-28 2022-03-31 四川科伦博泰生物医药股份有限公司 吡唑类化合物及其制备方法和用途
CN114437082B (zh) * 2020-11-06 2025-04-04 江苏先声药业有限公司 喹啉类化合物
CN115703750B (zh) * 2021-08-17 2024-07-02 黑龙江华瑞生物科技有限公司 一种1-氨基-4-甲基哌嗪的提取纯化方法
CN114249742B (zh) * 2021-11-22 2022-11-01 郑州大学 一种光气探针、荧光书写检测笔及其在光气检测中的应用
CN115969801B (zh) * 2023-03-21 2023-08-25 劲方医药科技(上海)有限公司 用于癌症的药物组合物及其制备方法
WO2024258967A1 (en) 2023-06-13 2024-12-19 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses
GB202309553D0 (en) 2023-06-24 2023-08-09 Ucl Business Ltd Compostions and uses thereof
CN118652155A (zh) * 2024-06-17 2024-09-17 南京工业大学 一种二芳基乙炔的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356897A (en) * 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
DK0649425T3 (da) * 1992-06-17 1999-09-27 Upjohn Co Pyridino-, pyrrolidino- og azepino-substituerede oximer, som er anvendelige som anti-atherosklerose- og anti-hypercholester
GB9303993D0 (en) * 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
AU7237294A (en) 1993-07-27 1995-02-28 Kyowa Hakko Kogyo Co. Ltd. Remedy for parkinson's disease
US5358947A (en) 1993-09-13 1994-10-25 American Cyanamid Company Angiotensin II receptor blocking 2,3-substituted pyrazolo[1,5-a]-1,3,5-triazin-4(3H)-ones
AUPN419395A0 (en) * 1995-07-17 1995-08-10 Treescope Development Co. Pty. Ltd. Plant protector
FR2746306B1 (fr) 1996-03-22 1998-04-30 Oreal Compositions de teinture des fibres keratiniques contenant des pyrazolo-azoles ; leur utilisation pour la teinture comme coupleurs, procede de teinture
AU754830C (en) 1997-05-22 2004-02-12 G.D. Searle Llc Substituted pyrazoles as p38 kinase inhibitors
FR2772379B1 (fr) 1997-12-16 2000-02-11 Oreal Compositions de teinture des fibres keratiniques contenant des pyrazolo-azoles; leur utilisation pour la teinture comme base d'oxydation, procede de teinture; nouveaux pyrazolo-azoles
GB9809869D0 (en) 1998-05-09 1998-07-08 Medical Res Council Inhibition of protein kinases
WO2000044743A1 (en) 1999-01-28 2000-08-03 Nippon Shinyaku Co., Ltd. Amide derivatives and drug compositions
AU4798000A (en) 1999-04-09 2000-11-14 Smithkline Beecham Corporation Triarylimidazoles
JP2003508401A (ja) * 1999-08-27 2003-03-04 アボット・ラボラトリーズ Ｃｏｘ−２阻害薬として有用なスルホニルフェニルピラゾール化合物
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
WO2002034716A2 (en) * 2000-10-11 2002-05-02 Merck & Co., Inc. Pyrrolidine modulators of ccr5 chemokine receptor activity
DE60203263T2 (de) 2001-02-02 2006-02-09 Smithkline Beecham Corp. Pyrazolderivate gegen tgf überexprimierung
HRP20030961B1 (en) * 2001-05-24 2012-01-31 Eli Lilly And Company Novel pyrrole derivatives as pharmaceutical agents
BRPI0410699A (pt) * 2003-05-28 2006-06-20 M & J Fibretech As método e distribuidor de fibras para a deposição a ar de fibras
JP4882198B2 (ja) 2003-09-25 2012-02-22 日産自動車株式会社 燃料電池システム

Also Published As

Publication number Publication date
IL158512A0 (en) 2004-05-12
CA2446820A1 (en) 2002-11-28
PT1397364E (pt) 2007-10-22
CN1951939A (zh) 2007-04-25
EP1397364A1 (en) 2004-03-17
ZA200308546B (en) 2005-04-26
DZ3506A1 (fr) 2002-11-28
HUP0400451A3 (en) 2008-08-28
MXPA03010630A (es) 2004-03-09
AU2002339268B2 (en) 2007-05-31
NO20035193D0 (no) 2003-11-21
NO326701B1 (no) 2009-02-02
JP4519407B2 (ja) 2010-08-04
UA76461C2 (en) 2006-08-15
AR036034A1 (es) 2004-08-04
BR0209939A (pt) 2004-03-30
KR100861630B1 (ko) 2008-10-07
CN1269820C (zh) 2006-08-16
TWI329644B (en) 2010-09-01
CY1106871T1 (el) 2012-09-26
EG25614A (en) 2012-03-22
CN1511157A (zh) 2004-07-07
HK1064375A1 (en) 2005-01-28
DE60221392T2 (de) 2008-04-17
HU228844B1 (en) 2013-06-28
HRP20030961A2 (en) 2005-08-31
CZ303808B6 (cs) 2013-05-09
JP2004535404A (ja) 2004-11-25
EA200301289A1 (ru) 2004-06-24
ATE368041T1 (de) 2007-08-15
WO2002094833A1 (en) 2002-11-28
EP1397364B1 (en) 2007-07-25
NO20035193L (no) 2003-11-21
CA2446820C (en) 2010-07-13
US7087626B2 (en) 2006-08-08
SV2003001054A (es) 2003-03-18
MY134586A (en) 2007-12-31
NZ528525A (en) 2005-10-28
HRP20030961B1 (en) 2012-01-31
US20040106604A1 (en) 2004-06-03
SK287857B6 (sk) 2012-01-04
KR20030097895A (ko) 2003-12-31
IL158512A (en) 2009-07-20
HUP0400451A2 (hu) 2004-12-28
PL221339B1 (pl) 2016-03-31
CZ20033128A3 (cs) 2004-06-16
ECSP034859A (es) 2004-01-28
PE20030117A1 (es) 2003-02-12
ES2289116T3 (es) 2008-02-01
SK14162003A3 (en) 2004-11-03
DE60221392D1 (de) 2007-09-06
DK1397364T3 (da) 2007-11-26
CO5540282A2 (es) 2005-07-29
PL367199A1 (en) 2005-02-21
EA007782B1 (ru) 2007-02-27
JP2009197016A (ja) 2009-09-03

Similar Documents

Publication Publication Date Title
IL158512A0 (en) Novel pyrrole derivatives as pharmaceutical agents
EP1450824A4 (en) PHARMACEUTICAL COMPOSITION
GB0111597D0 (en) Pharmaceutical compositions
IL158388A0 (en) Novel arylheteroalkylamine derivatives
HUP0303163A3 (en) Tramadol-based pharmaceutical composition
GB0117057D0 (en) Pharmaceutical composition
GB0101227D0 (en) Pharmaceutical compounds
GB0129117D0 (en) Pharmaceutical composition
EP1408896A4 (en) PHARMACEUTICAL COMPOSITION
GB0101225D0 (en) Pharmaceutical compounds
GB0026578D0 (en) Heterocyclic derivatives useful as pharmaceutical agents
GB0116107D0 (en) Pharmaceutical composition
GB0104752D0 (en) Pharmaceutical compositions
GB0127805D0 (en) Pharmaceutical composition
PL370037A1 (en) Pharmaceutical composition
GB0129872D0 (en) Novel pharmaceutical
GB0127720D0 (en) Pharmaceutical compositions
IL157411A0 (en) Pharmaceutical composition
GB0130509D0 (en) Novel pharmaceutical
GB0129876D0 (en) Novel pharmaceutical
GB0130510D0 (en) Novel pharmaceutical
GB0130511D0 (en) Novel pharmaceutical
HU0103049D0 (en) Pharmaceutical composition
GB0125061D0 (en) Pharmaceutical composition
GB0129871D0 (en) Novel pharmaceutical